Literature DB >> 31394196

Chronic Cerebral Hypoperfusion Activates the Coagulation and Complement Cascades in Alzheimer's Disease Mice.

Xiaowen Shi1, Yasuyuki Ohta1, Xia Liu1, Jingwei Shang1, Ryuta Morihara1, Yumiko Nakano1, Tian Feng1, Yong Huang1, Kota Sato1, Mami Takemoto1, Nozomi Hishikawa1, Toru Yamashita1, Koji Abe2.   

Abstract

Alzheimer's disease (AD) in the elderly is frequently accompanied by chronic cerebral hypoperfusion (CCH), which impairs the clearance of amyloid beta (Aβ) due to the dysfunction of the blood-brain barrier (BBB) and accelerates the AD pathology. Since the coagulation and complement cascades are associated with BBB dysfunction and AD pathology, we investigated the expression changes of coagulation (fibrinogen alpha chain-FGA, coagulation factor XIII A chain-Factor XIIIα) and complement (plasma protease C1 inhibitor-C1-INH, Complement component 3-C3) factors in the brain of novel AD model (APP23) mice with CCH at 12 months of age. Immunohistochemical and immunofluorescent analysis showed that the expressions of FGA, Factor XIIIα, C1-INH and C3 were significantly increased in cerebral neocortex, hippocampus, and thalamus of APP23 + CCH group (n = 12) as compared with wild type (WT, n = 10) and APP23 (n = 10) groups (⁎P < .05 and ⁎⁎P < .01 vs WT; #P < .05 and ##P < .01 vs APP23), especially near and inside of neurovascular unit. The present study suggests that CCH activated both the coagulation and complement cascades in a novel AD model mice brain accompanied by the acceleration of AD pathology.
Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APP23 mice; Alzheimer's disease; blood–brain barrier; chronic cerebral hypoperfusion; coagulation; complement

Mesh:

Substances:

Year:  2019        PMID: 31394196     DOI: 10.1016/j.neuroscience.2019.07.050

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  Mineralocorticoid receptor antagonism improves transient receptor potential vanilloid 4-dependent dilation of cerebral parenchymal arterioles and cognition in a genetic model of hypertension.

Authors:  Laura C Chambers; Janice M Diaz-Otero; Courtney L Fisher; William F Jackson; Anne M Dorrance
Journal:  J Hypertens       Date:  2022-09-01       Impact factor: 4.776

Review 2.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

3.  Deficiency of Complement Component C1Q Prevents Cerebrovascular Damage and White Matter Loss in a Mouse Model of Chronic Obesity.

Authors:  Leah C Graham; Heidi E Kocalis; Ileana Soto; Gareth R Howell
Journal:  eNeuro       Date:  2020-06-11

4.  A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.

Authors:  Koji Abe; Jingwei Shang; Xiaowen Shi; Toru Yamashita; Nozomi Hishikawa; Mami Takemoto; Ryuta Morihara; Yumiko Nakano; Yasuyuki Ohta; Kentaro Deguchi; Masaki Ikeda; Yoshio Ikeda; Koichi Okamoto; Mikio Shoji; Masamitsu Takatama; Motohisa Kojo; Takeshi Kuroda; Kenjiro Ono; Noriyuki Kimura; Etsuro Matsubara; Yosuke Osakada; Yosuke Wakutani; Yoshiki Takao; Yasuto Higashi; Kyoichi Asada; Takehito Senga; Lyang-Ja Lee; Kenji Tanaka
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 5.  Neurodegenerative Disorders of the Eye and of the Brain: A Perspective on Their Fluid-Dynamical Connections and the Potential of Mechanism-Driven Modeling.

Authors:  Giovanna Guidoboni; Riccardo Sacco; Marcela Szopos; Lorenzo Sala; Alice Chandra Verticchio Vercellin; Brent Siesky; Alon Harris
Journal:  Front Neurosci       Date:  2020-11-12       Impact factor: 4.677

Review 6.  Role of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer's Disease.

Authors:  Hareram Birla; Tarun Minocha; Gaurav Kumar; Anamika Misra; Sandeep Kumar Singh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.